Facts and figures
General information
Headquarters in Denmark.
Worldwide: Production facilities in six countries, affiliates or offices in 79 countries.
Workforce: 23,613 employees.
Novo Nordisk’s workforce is growing outside Denmark: 53% of employees are located in Denmark, 47% in the rest of the world.
- 4,105 in research and development
- 8,402 in production
- 6,995 in sales and marketing
- 4,111 in administration
Land
All Novo Nordisk's facilities in Denmark, plus our production sites outside Denmark, are located on land which is either owned or leased by Novo Nordisk. In total, the company owns and leases 4,202,264 hectares for its production activities. It does not own, lease or manage land for extractive use.
Product areas
Diabetes care
Haemostasis management (NovoSeven®)
Growth hormone therapy
Hormone replacement therapy (HRT)
Sales by business segment
Sales: 38,743 million Danish kroner (full year 2006).
- Diabetes care: 27,866 million Danish kroner
- Biopharmaceuticals: 10,877 million Danish kroner
Sales by region
Sales growth was realised in all regions measured in local currencies. North America and Europe were the main growth drivers contributing 53% and 23% respectively, of the total sales growth for 2006. Solid growth was also realised in International Operations, contributing 20% of the total sales growth, whereas sales in Japan and Oceania were impacted negatively by a mandatory reduction in reimbursement prices in Japan as of 1 April 2006.
- Europe: 14,708 million Danish kroner
- Japan & Oceania: 4,669 million Danish kroner
- North America: 12,280 million Danish kroner
- International Operations: 7,086 million Danish kroner
This page has been assessed by PricewaterhouseCoopers as part of its assessment of Novo Nordisk’s statement that it reports ‘in accordance’ with GRI. Please refer to Audit and assurance for a full description of the nature of assurance offered.
